Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.

BMC Rheumatol · 2021 · PMC8008554 · PMID 33781343

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

Treatment with either lanraplenib (0.25%) or cyclophosphamide showed an overall trend toward a reduction in the proinflammatory cytokine concentrations.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.